A Phase 1-2, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 03 Mar 2015
At a glance
- Drugs Namodenoson (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Can-Fite BioPharma
- 28 Aug 2013 Data from this study were published in The Oncologist in January 2013, and will be presented at the 18th World Congress on Advances in Oncology, according to a Can-Fite BioPharma media release.
- 01 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 03 Jan 2012 Results published in a Can-Fite BioPharma media release.